Reassure Study: The Real-World Evidence Initiative in Recurrent early pregnancy loss - Video

Recurrent early pregnancy loss (REPL) has long been marked by uncertainty, limited evidence, and treatments that offered hope without proven outcomes—resulting in only 87% of pregnancies progressing successfully.

A breakthrough has emerged with Reassure, the first global real-world evidence initiative in REPL: a multicentric observational study involving 828 women across 166 centers.

The study demonstrated that 92.3% of pregnancies continued beyond 20 weeks when treated with dydrogesterone ER 20 mg, representing a major advance in care.

What began as a journey of unanswered questions now moves from doubt to hope, offering a future focused on supporting life.